Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

28 Dec 2010

Fried fish consumption linked to high stroke rates: Study

Researchers from Emory University (Atlanta, Georgia), the University of Alabama (Birmingham, Alabama), and Boston University (Boston, University) have found that omega-3 fatty acids contained in fish has “favourable effects on platelet aggregation, blood pressure, lipid profile, endothelial function, and ischemic stroke risk.” The team led by Dr. Fadi Nahab decided to look into the racial and geographical aspects of preparing and eating fish and its effects.

28 Dec 2010

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Researchers at the Methodist DeBakey Heart & Vascular Center in Houston were recently awarded a $6.78 million grant from the National Institutes of Health to extend a 23-year-old large-scale, community-based study of heart disease.

27 Dec 2010

HIT interventions promising tools in fight to improve medication adherence, despite paucity of data

A new study that reviews more than four decades of medical journal articles about the impact of health information technology (HIT) and electronic communications on medication adherence concludes that while there is evidence to suggest that simple electronic reminders are an effective and low-cost means to improve adherence, there are few studies that show how HIT can be leveraged to more thoughtfully engage or motivate patients to take medications as prescribed.

24 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Paternal diet affects lipid metabolizing genes in offspring

Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.

24 Dec 2010

New era for anticoagulant therapy

In a Guest Editorial published in the new publication Clinical Investigation, Dr Jeffrey Weitz and Dr John Eikelboom of McMaster University in Hamilton, Canada highlight the importance of the approval in October by the FDA of dabigatran etexilate (Pradaxa®; Boehringer Ingelheim). This new oral thrombin inhibitor provides an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.

22 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Healthy foods improve survival and quality of life in older adult population

In a study published in the January 2011 issue of the Journal of the American Dietetic Association, researchers investigated empirical data regarding the associations of dietary patterns with mortality through analysis of the eating patterns of over 2500 adults between the ages of 70 and 79 over a ten-year period.

22 Dec 2010

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

22 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Magellan, ACG partner to train specialists to provide Peer Support Whole Health services

Magellan Health Services, Inc., an industry leader in behavioral health care management, and Appalachian Consulting Group (ACG) have joined forces to train peer specialists to provide Peer Support Whole Health (PSWH) services. PSWH, an evidence-based behavioral health practice that is growing in use across the country, focuses on improving the overall physical and mental health of individuals with mental illnesses to help them achieve their health and wellness goals.

21 Dec 2010

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

AstraZeneca’s new blood thinner that was pitched against Plavix, the world’s second-best selling drug failed to live up to expectations making stocks drop to a two year low, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.

20 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces positive pre-clinical results from its in-house product candidate C3BS-GQR-1, to treat patients suffering from acute myocardial infarction in order to protect cardiac tissue from damage and direct heart stem cells to mature and restore pump function.

20 Dec 2010

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Fried fish consumption linked to high stroke rates: Study

Researchers receive $6.78 million NIH grant for community-based study on heart disease

HIT interventions promising tools in fight to improve medication adherence, despite paucity of data

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Paternal diet affects lipid metabolizing genes in offspring

New era for anticoagulant therapy

Top ten advances in cardiovascular, stroke research in 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Amorcyte reports AMR-001 phase I trial results in heart attack patients

Healthy foods improve survival and quality of life in older adult population

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Magellan, ACG partner to train specialists to provide Peer Support Whole Health services

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

VIVUS seeks marketing approval of QNEXA in the EU

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Newsletters you may be interested in